Acute brain injury can result in neuroprotection and tolerance to subsequent injury. However, the mechanisms of this endogenous neuroprotection are incompletely known. As the increase in adenosine following acute seizures is both neuroprotective and antiepileptic, adenosine may also provide neuroprotection and tolerance in ischemia. The elevation of adenosine following acute seizures is due to downregulation of adenosine kinase (ADK), the key enzyme of adenosine metabolism. Thus, the adenosine- ADK system may be a candidate as an endogenous tolerance effector.
We aim to investigate how ADK is regulated in response to ischemic brain injury and how these findings can be translated into applications to prevent damage to the injured brain. The rationale for these studies is derived from the following previous findings from our lab: (1) ADK is rapidly and transiently downregulated as an acute response to both injurious seizures and transient focal cerebral ischemia. (2) Upregulation of ADK renders the brain more vulnerable to ischemic cell loss. (3) Intrastriatal implants of adenosine releasing stem cells protect the brain from subsequent ischemia. (4) Pharmacological blockade or RNAi-mediated downregulation of ADK effectively suppress seizures and seizure-induced injury. Our CENTRAL HYPOTHESIS is that the acute and transient downregulation of ADK after an insult is a general phenomenon of injury and responsible for the induction of ischemic tolerance and that augmentation and prolongation of this beneficial ADK-response is neuroprotective. We will investigate ADK expression in rodent models of ischemia. In a therapeutic approach ischemic tolerance will be induced by inhibiting ADK expression by lentiviral RNAi.
The SPECIFIC AIMS of this project are:
Aim 1. Study the involvement of the adenosine system in the induction of ischemic tolerance.
Aim 2. Induce tolerance by therapeutic downregulation of ADK.

Public Health Relevance

We plan to investigate novel mechanisms and strategies to prevent cell loss after stroke. Therapeutically, augmentation of the brain's endogenous neuroprotective adenosine system is expected to induce tolerance to ischemic brain injury. Our findings may be translated into effective new therapies for the prevention of brain damage after stroke. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21NS057538-01A2
Application #
7468902
Study Section
Clinical Neuroscience and Disease Study Section (CND)
Program Officer
Golanov, Eugene V
Project Start
2008-04-01
Project End
2010-03-31
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
1
Fiscal Year
2008
Total Cost
$172,484
Indirect Cost
Name
Emanuel Hospital and Health Center
Department
Type
DUNS #
050973098
City
Portland
State
OR
Country
United States
Zip Code
97232
Boison, Detlev (2011) Modulators of nucleoside metabolism in the therapy of brain diseases. Curr Top Med Chem 11:1068-86
Boison, Detlev (2011) Methylxanthines, seizures, and excitotoxicity. Handb Exp Pharmacol :251-66
Shen, Hai-Ying; Lusardi, Theresa A; Williams-Karnesky, Rebecca L et al. (2011) Adenosine kinase determines the degree of brain injury after ischemic stroke in mice. J Cereb Blood Flow Metab 31:1648-59
Boison, D; Chen, J-F; Fredholm, B B (2010) Adenosine signaling and function in glial cells. Cell Death Differ 17:1071-82
Boison, Detlev (2010) Adenosine dysfunction and adenosine kinase in epileptogenesis. Open Neurosci J 4:93-101
Boison, Detlev; Shen, Hai-Ying (2010) Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death. Open Drug Discov J 2:108-118
Van Dycke, Annelies; Verstraete, Alain; Pil, Kristof et al. (2010) Quantitative analysis of adenosine using liquid chromatography/atmospheric pressure chemical ionization-tandem mass spectrometry (LC/APCI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 878:1493-8
Van Dycke, Annelies; Raedt, Robrecht; Verstraete, Alain et al. (2010) Astrocytes derived from fetal neural progenitor cells as a novel source for therapeutic adenosine delivery. Seizure 19:390-6
Boison, Detlev; Stewart, Kerry-Ann (2009) Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation. Biochem Pharmacol 78:1428-37
Boison, Detlev (2009) Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies. Epilepsy Res 85:131-41

Showing the most recent 10 out of 13 publications